A 104 WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY OF ALISKIREN ON THE PROGRESSION OF ATHEROSCLEROSIS IN PATIENTS WITH CORONARY ARTERY DISEASE WHEN ADDED TO OPTIMAL BACKGROUND THERAPY
Principal Investigator(s)
Feldman,Marc David
Funded by
NOVARTIS PHARMACEUTICALS CORPORATION
Research Start Date
Status
Inactive